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Diabetes Association, FIN-33680, Tampere, Finland. pirjo.ilanne-parikka@diabetes.fi the beginning of 1996 and with incident diabetes diagnosed after that but no later than 31 December surveillance following newly diagnosed diabetes leads to increased detection of occult cancers during 133 the first year after diagnosis [27] . Women with prior hysterectomy were excluded from the cohort.
134
Data about hysterectomies was available post-1987, leaving the possibility of some hysterectomized 135 women remaining in the cohort. This especially concerned women in the older age categories.
136
Patients who had used systemic hormone replacement therapy (HRT) were removed from the cohort 137 to eliminate the effect of HRT on the incidence of EC and to exclude some of the women who had had Exposure to anti-diabetic medication was assessed in three categories: metformin, other types of oral 152 ADM and insulin (classification by ATC codes is shown in appendix 1). In addition the use of statins 153 was evaluated. Exposure to any medication was defined to begin 365 days after its purchase date in order to avoid reverse causality. Both in nested case-control analyses and in the full cohort analysis 155 patients were classified as exposed to the drug from this moment onwards throughout the follow-up 156 time (never-/ever-exposed). In addition, cumulative use of ADM and statins was estimated in nested 157 case-control analyses as summed amount of daily defined doses (DDD) during the follow-up period. 
Results
The final cohort consisted of 92,366 women diagnosed with type 2 diabetes between 1996 and 2011.
179
The total follow-up covered 503,937 person-years at risk. The mean follow-up time was 5.5 years. The 180 patients in the cohort were between 40 and 106 years of age. 590 women were diagnosed with 181 endometrioid endometrial cancer during the study period. From now on when regarding results from 182 our study, EC refers to endometrioid endometrial cancer.
183
The incidence of EC was age-dependent, reaching its peak in the group of women aged 65-69 years.
184
The incidence of EC was higher in patients in whom the duration of DM was over 8 years, compared 
189
The EC incidence in the chosen reference group (age 70-74 years, diabetes duration less than three 0.87-1.12). In contrast, use of statins at any time was inversely related to EC incidence (Table 2) .
196
In line with the results of the full-cohort analysis, "ever use" of metformin or other forms of oral ADM 197 was associated with an increased incidence of EC in nested case-control analyses. Ever use of insulin also appeared to be positively associated with the risk of EC. As in the full cohort analysis in nested 199 case-control analysis the incidence of EC was not found to be different between metformin ever-users In the present study metformin use was associated with an increased incidence of endometrioid 218 endometrial cancer in the full cohort (HR 1.23) as well as in the case-control analysis (HR 1.24) 219 compared to metformin "never use". Additionally, increasing cumulative use of metformin showed a tendency to predict an elevated risk of EC. Thus, our results speak against the EC risk-reducing effect of metformin.
222
Other forms of oral ADM were also related to an increased incidence of EC in our study. In our cohort 223 the oral types of ADM mostly included sulfonylureas (94.1%). In previous studies sulfonylureas have 224 been suggested to increase the incidence of cancer [30] . Our results are in line with these findings.
225
In our study insulin use was associated with an elevated risk of EC, both in the full-cohort (HR 1.19) 
233
One of the major strengths of our study lies in its time-dependent design. We were able to calculate that to some degree the lower cancer incidence observed in statin users in our study is related to 292 differences in health-seeking behavior compared with nonusers (healthy-user effect). To conclude, in our study in patients with T2D the use of metformin or other types of oral ADM was 306 not observed to be in concordance with the hypothesis that these forms of medication would have a protective effect as regards the risk of EC. Insulin users seemed to be at an increased risk of EC. Women with T2D in the register, n=244322
Death prior to cohort entry, n=7314
Hysterectomy prior to cohort entry, n=20904
HRT prior to cohort entry, n=43275
EC prior to or during the 1st year after cohort entry, n=2821
Diabetes diagnosed prior to study period, n=68688
Final cohort, n=92366
End of the study period before cohort entry, n=8954 
